SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.
Tradegate System der Deutsche Börse AG (60%)
Börse Tradegate System der Deutsche Börse AG (60%)
Symbol 1CG
EUR
  • CRISPR Therapeutics
    Börse Tradegate System der Deutsche Börse AG (60%)
    Symbol 1CG
    EUR
  • CRISPR Therapeutics
    Börse Börse Berlin
    Symbol 1CG
    EUR
  • CRISPR Therapeutics
    Börse Börse Stuttgart
    Symbol 1CG
    EUR
  • CRISPR Therapeutics
    Börse Börse Düsseldorf
    Symbol 1CG
    EUR
  • CRISPR Therapeutics
    Börse Börse München
    Symbol 1CG
    EUR
  • CRISPR Therapeutics
    Börse Börse Frankfurt
    Symbol 1CG
    EUR
  • CRISPR Therapeutics
    Börse Gettex System der Börse München
    Symbol 1CG
    EUR
  • CRISPR Therapeutics
    Börse Nasdaq
    ISIN CH0334081137 WKN: A2AT0Z
    Symbol CRSP
    USD
  • ISIN CH0334081137 WKN: A2AT0Z
    Symbol CRSP
    USD
  • MXN
  • USD
Symbol 1CG
Währung EUR
Börse Tradegate System der Deutsche Börse AG (60%) Zeitzone: Europe/London
Marktkapitalisierung 8.806.828.960 (+- 8%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

9.480.657.920 oder 8.133.000.000

Mitarbeiter 434 (+- 6%)

Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:

410 oder 458 Mitarbeiter

KGV 124.34
EBITDA 2.869.000
Buchwert 22.516

66 News & Informationen zur CRISPR Therapeutics Aktie

  • Crispr Therapeutics Ag (CRSP) CEO Samarth Kulkarni Sold $3.9 million of Shares
    gurufocus.com

    Crispr Therapeutics Ag (CRSP) CEO Samarth Kulkarni Sold $3.9 million of Shares

    GuruFocus Article or News written by insider and the topic is about:

  • Why CRISPR Therapeutics Stock Fell 25.2% in July
    fool.com

    Why CRISPR Therapeutics Stock Fell 25.2% in July

    The stock dropped roughly $40 per share over the course of the month.

  • Cathie Wood’s ARK Invest Doubles Down on Buying This Biotech-Focused SPAC – 24/7 Wall St.
    247wallst.com

    Cathie Wood’s ARK Invest Doubles Down on Buying This Biotech-Focused SPAC – 24/7 Wall St.

    On August 5, one ARK Invest fund bought nearly 2 million shares of Soaring Eagle Acquisition, a biotech-focused special purpose acquisition company. This is adding to the 4 million shares it bought on Thursday.

  • S&P, NASDAQ Set New Highs While Waiting for Jobs Report
    investing.com

    S&P, NASDAQ Set New Highs While Waiting for Jobs Report

    Stocks Analysis by Zacks Investment Research covering: Cross Country Healthcare Inc, Pacific Biosciences of California, Materion Corporation, Editas Medicine Inc. Read Zacks Investment Research's latest article on Investing.com

  • CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
    marketscreener.com

    CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference

    ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 05, 2021 — CRISPR Therapeutics , a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today… | August 5, 2021

  • Cathie Wood’s ARK Invest Buys for 8
    247wallst.com

  • Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?
    fool.com

    Is This Small-Cap Biotech a Buy After Its Second Approved Gene Therapy?

    After receiving yet another treatment approval from regulators, Bluebird Bio looks like a bargain.

  • Better Buy: Vertex vs. CRISPR
    fool.com

    Better Buy: Vertex vs. CRISPR

    Vertex might be undervalued, CRISPR Therapeutics might be overvalued, but both are looking for a home run.

  • CRISPR Therapeutics AG (CRSP) Tops Q2 Earnings and Revenue Estimates
    zacks.com

    CRISPR Therapeutics AG (CRSP) Tops Q2 Earnings and Revenue Estimates

    CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 125.30% and 32.84%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

  • CRISPR Therapeutics : More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of...
    marketscreener.com

    CRISPR Therapeutics : More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 (Form 8-K)

    – More than 45 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021-

    … | July 29, 2021

  • CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
    zacks.com

    CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

    In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $119, marking a -0.63% move from the previous day.

  • Is CRISPR Therapeutics a Millionaire-Maker Stock?
    fool.com

  • 3 Things About CRISPR Therapeutics That Smart Investors Know
    fool.com

    3 Things About CRISPR Therapeutics That Smart Investors Know

    The company is on track to be the first to market with a gene-editing therapy for blood disorders.

  • Arkk has some new direct competition : investing
    reddit.com

    Arkk has some new direct competition : investing

    The Jacob Forward ETF (JFWD) launched on Wednesday, trading on the NYSE Arca. In an interview, Jacob admits there are plenty of similarities between …

  • 3 Things About Vertex Pharmaceuticals That Smart Investors Know
    fool.com

    3 Things About Vertex Pharmaceuticals That Smart Investors Know

    Can one multibillion-dollar blockbuster breakthrough lead to another?

  • Traynor Capital Management, Inc. Buys DoorDash Inc, Airbnb Inc, CRISPR Therapeutics AG, Sells MercadoLibre Inc, Atomera Inc, ARK Innovation...
    gurufocus.com

    Traynor Capital Management, Inc. Buys DoorDash Inc, Airbnb Inc, CRISPR Therapeutics AG, Sells MercadoLibre Inc, Atomera Inc, ARK Innovation ETF

    GuruFocus Article or News written by insider and the topic is about:

  • Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending
    markets.businessinsider.com

    Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending

    According to Goldman Sachs, mergers and acquisitions have reached new heights in 2021. Ramin Talaie/Getty Images Goldman Sachs says S&P 50…

  • Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending
    markets.businessinsider.com

    Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending

    According to Goldman Sachs, mergers and acquisitions have reached new heights in 2021. Ramin Talaie/Getty Images Goldman Sachs says S&P 50…

  • Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending
    markets.businessinsider.com

    Goldman Sachs details 19 stocks that could fetch large premiums as acquisition targets amid a 45% spike in M&A spending

    According to Goldman Sachs, mergers and acquisitions have reached new heights in 2021. Ramin Talaie/Getty Images Goldman Sachs says S&P 50…

  • CRISPR Therapeutics AG (CRSP) Stock Moves -0.67%: What You Should Know
    zacks.com

    CRISPR Therapeutics AG (CRSP) Stock Moves -0.67%: What You Should Know

    CRISPR Therapeutics AG (CRSP) closed at $126.25 in the latest trading session, marking a -0.67% move from the prior day.

  • Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
    fool.com

    Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week

    After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains.

  • Apis Capital Deep Value Fund 2Q21 Commentary
    valuewalk.com

    Apis Capital Deep Value Fund 2Q21 Commentary

    Apis Capital Deep Value Fund was up 2.8% net in Q2 2021. During the past quarter, our longs contributed 9.2 percent (gross).

  • Jim Cramer’s Top Picks to Stand Up to Inflation – 24
    247wallst.com

    Jim Cramer’s Top Picks to Stand Up to Inflation – 24

    24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.

  • Vera Therapeutics Appoints Sean Grant as Chief Financial Officer
    globenewswire.com

    Vera Therapeutics Appoints Sean Grant as Chief Financial Officer

    Healthcare and financial services industry veteran brings nearly 15 years of multi-disciplinary financial experience and proven track record in strategic…

  • Should I Buy WEX Inc (WEX)?
    insidermonkey.com

    Should I Buy WEX Inc (WEX)?

    At Insider Monkey, we pore over the filings of nearly 866 top investment firms every quarter, a process we have now completed for the latest reporting…

  • Is The Middleby Corporation (MIDD) A Good Stock To Buy?
    insidermonkey.com

    Is The Middleby Corporation (MIDD) A Good Stock To Buy?

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….

Schreibe einen Kommentar

Wenn du schon einen Account hast, logge dich ein bevor du den Kommentar absendest.

Galue Account Vorteile
  • Battles

    Messe dich mit der Community in Battles.

  • Badges

    Erhalte Belohnungen für Kommentare, die der Community helfen.

  • Mehr Informationen für alle

    Poste Bilder oder Videos zu Themen und Unternehmen und helf dabei, dass Investoren ein kontroverseres Bild erhalten.

  • Kein Datenrisiko

    Du kannst jederzeit deinen Account löschen und gespeicherte Daten einsehen.

Portrait der CRISPR Therapeutics Aktie

Das Unternehmen CRISPR Therapeutics AG aus USA beschäftigt 434 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Gesundheitsdienstleistungen tätig.

Das Unternehmen CRISPR Therapeutics AG ist in ungefähr 13 ETFs enthalten und somit eine nicht sonderlich bekannte oder beliebte Aktie. Der Spitzenreiter Global X Genomics & Biotechnology ETF gewichtet CRISPR Therapeutics mit 3,84% im ETF.

Entdecke die 6 ETFs in denen CRISPR Therapeutics AG am höchsten gewichtet ist Insgesamt in 13 ETFs enthalten

Dir gefallen die Informationen zu CRISPR Therapeutics?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:

Zur ING Diba

Dir gefallen die Informationen zu CRISPR Therapeutics?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:

Zu BUX Zero

Dir gefallen die Informationen zu CRISPR Therapeutics?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:

Zur Comdirect

Dir gefallen die Informationen zu CRISPR Therapeutics?

Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:

Zu Trade Republic